In vitro Inhibition of Brain Glutamic Acid Decarboxylase by Sodium 2-mercaptoethanesulphonate and Endogenous Thiols and its Possible in vivo Consequences

Meanwell C. , Blake AE , Blackledge G. , et al. Encephalopathy associated with ifosfamide/mesna therapy Lancet 1985; i: 406-7.

Cantwell Bmj & Harris AL Ifosfamide/mesna and encephalopathy Lancet 1985; i: 752.

Lamar C. Mercaptopropionic acid: a convulsant that inhibits glutamate decarboxylase Journal of Neuro-chemistry 1970; 17: 165-70.

VanDyk JJ , Falkson HC , van der Merwe AM & Falkson G. Unexpected toxicity in patients treated with ifosfamide Cancer Research 1972; 32: 921-4.

Albers RW & Brady RO The distribution of glutamic decarboxylase in the nervous system of the Rhesus monkey. Journal of Biological Chemistry 1959 ; 234: 926-8.

Oldendorf WH Brain uptake of radiolabelled amino acids, amines and hexoses after arterial injection. American Journal of Physiology 1971; 222: 1629-39.

Shaw IC & Graham MI Mesna-a short review. Cancer Treatment Reviews 1987; 14: 67-86.

Sidau B. & Shaw IC Determination of sodium 2-mercaptoethanesulphonate by HPLC using post column reaction colorimetry or electrochemical detection. Cancer Treatment Reviews 1984; 311: 234-8.

Wright KE , Garrod P. & Shaw IC Mechanism of enhanced cysteine excretion in urine during sodium 2-mercaptoethanesulphonate (mesna) administration Human Toxicology 1985 ; 4: 456.

Sangster G. , Kaye SV , Calman KC & Dalton JF Failure of 2-mercaptoethanesulphonate sodium (mesna) to protect against ifosfamide nephrotoxicity European Journal of Cancer and Clinical Pharmacology 1984; 20: 435-6.